Genetic testing for Rh variants improves transfusion safety
Comprehensive Rh blood typing and genetic analysis can help prevent HDFN and reduce transfusion-related complications.
Comprehensive Rh blood typing and genetic analysis can help prevent HDFN and reduce transfusion-related complications.
Better transfusion record sharing through the Alloantibody Exchange can prevent dangerous delays in identifying antibodies that cause HDFN.
Most infants in the study with Rh-linked hemolytic disease were born with high iron levels that can persist for up to a year.
A review of 238 studies on HDFN showed 104 different outcomes reported with major differences in how they were defined and measured.
Infants with severe neonatal jaundice, a symptom of HDFN, showed higher blood levels of a heart injury marker in a recent study.
A Nigerian study found that nearly 5% of pregnant women carried antibodies that could cause hemolytic disease of the fetus and newborn.
A recent study found no cases of HDFN or autoimmune hemolytic anemia in women or their children despite the presence of these antibodies.
Newborns with HDFN face a greater risk of necrotizing enterocolitis, a dangerous intestinal condition, especially after certain treatments.
Genetic blood testing can spot rare blood type differences that standard tests may miss, which could help prevent HDFN.
The report highlights how anti-Rh17 antibodies in mothers with a rare Rh phenotype can cause HDFN, leading to severe anemia and jaundice.